Share on StockTwits

Investment analysts at Barclays decreased their price objective on shares of Bioamber (NASDAQ:BIOA) from $22.00 to $20.00 in a note issued to investors on Thursday. Barclays’ target price would suggest a potential upside of 68.49% from the stock’s previous close.

In other Bioamber news, EVP Michael A. Hartmann bought 3,000 shares of the company’s stock in a transaction dated Wednesday, July 16th. The shares were purchased at an average cost of $12.00 per share, with a total value of $36,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Bioamber (NASDAQ:BIOA) traded up 0.59% during mid-day trading on Thursday, hitting $11.87. The stock had a trading volume of 301,557 shares. Bioamber has a 1-year low of $3.96 and a 1-year high of $15.29. The stock’s 50-day moving average is $10.65 and its 200-day moving average is $11.11. The company’s market cap is $220.4 million.

Bioamber (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.01. On average, analysts predict that Bioamber will post $-1.84 earnings per share for the current fiscal year.

BioAmber Inc (NASDAQ:BIOA) is a chemical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.